Paxman AB (publ) (PAX.ST)
SEK 65.0
(0.0%)
SEK 65.0
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 12.61 Million SEK | -87.56% |
| 2022 | 101.43 Million SEK | 57.22% |
| 2021 | 64.51 Million SEK | 27.28% |
| 2020 | 50.68 Million SEK | -20.85% |
| 2019 | 64.03 Million SEK | 40.82% |
| 2018 | 45.47 Million SEK | 79.68% |
| 2017 | 25.3 Million SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 10.6 Million SEK | 43.16% |
| 2024 Q1 | 7.4 Million SEK | 62.25% |
| 2023 Q3 | 41.95 Million SEK | 22.87% |
| 2023 FY | 12.61 Million SEK | -87.56% |
| 2023 Q1 | 29.61 Million SEK | 2.37% |
| 2023 Q2 | 34.14 Million SEK | 15.28% |
| 2023 Q4 | 4.56 Million SEK | -89.12% |
| 2022 Q1 | 18.33 Million SEK | -9.27% |
| 2022 Q4 | 28.93 Million SEK | -3.36% |
| 2022 Q3 | 29.93 Million SEK | 23.55% |
| 2022 Q2 | 24.23 Million SEK | 32.18% |
| 2022 FY | 101.43 Million SEK | 57.22% |
| 2021 Q1 | 14.66 Million SEK | 49.1% |
| 2021 Q2 | 14.58 Million SEK | -0.56% |
| 2021 Q3 | 15.06 Million SEK | 3.3% |
| 2021 Q4 | 20.2 Million SEK | 34.13% |
| 2021 FY | 64.51 Million SEK | 27.28% |
| 2020 Q1 | 17.39 Million SEK | -1.47% |
| 2020 Q3 | 11.65 Million SEK | -1.18% |
| 2020 Q4 | 9.83 Million SEK | -15.62% |
| 2020 FY | 50.68 Million SEK | -20.85% |
| 2020 Q2 | 11.79 Million SEK | -32.2% |
| 2019 Q4 | 17.65 Million SEK | 5.64% |
| 2019 FY | 64.03 Million SEK | 40.82% |
| 2019 Q1 | 13.85 Million SEK | 15.12% |
| 2019 Q2 | 15.81 Million SEK | 14.16% |
| 2019 Q3 | 16.71 Million SEK | 5.7% |
| 2018 Q3 | 13.1 Million SEK | 25.44% |
| 2018 Q4 | 12.03 Million SEK | -8.19% |
| 2018 Q2 | 10.44 Million SEK | 5.66% |
| 2018 FY | 45.47 Million SEK | 79.68% |
| 2018 Q1 | 9.88 Million SEK | 50.62% |
| 2017 FY | 25.3 Million SEK | 0.0% |
| 2017 Q1 | 5.09 Million SEK | 0.0% |
| 2017 Q2 | 6.66 Million SEK | 30.9% |
| 2017 Q3 | 8.1 Million SEK | 21.48% |
| 2017 Q4 | 6.56 Million SEK | -18.95% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Acarix AB (publ) | 5.29 Million SEK | -138.21% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 95.802% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 95.802% |
| Arcoma AB | 11.07 Million SEK | -13.973% |
| Bactiguard Holding AB (publ) | 139.98 Million SEK | 90.986% |
| BICO Group AB (publ) | 1.83 Billion SEK | 99.311% |
| Boule Diagnostics AB (publ) | 249.71 Million SEK | 94.947% |
| CellaVision AB (publ) | 463.04 Million SEK | 97.275% |
| Clinical Laserthermia Systems AB (publ) | 2.99 Million SEK | -321.021% |
| Chordate Medical Holding AB (publ) | -28.41 Million SEK | 144.408% |
| C-Rad AB (publ) | 66.01 Million SEK | 80.886% |
| Duearity AB (publ) | -4.17 Million SEK | 402.011% |
| Dignitana AB (publ) | 58.97 Million SEK | 78.603% |
| Episurf Medical AB (publ) | -41.8 Million SEK | 130.187% |
| Getinge AB (publ) | 13.43 Billion SEK | 99.906% |
| Scandinavian Real Heart AB (Publ) | -50.21 Million SEK | 125.127% |
| Iconovo AB (publ) | 17.57 Million SEK | 28.216% |
| Integrum AB (publ) | 690.56 Thousand SEK | -1727.207% |
| Luxbright AB (publ) | -2.79 Million SEK | 551.146% |
| Mentice AB (publ) | 236.38 Million SEK | 94.662% |
| OssDsign AB (publ) | 83.64 Million SEK | 84.915% |
| Promimic AB (publ) | 38.51 Million SEK | 67.239% |
| Qlife Holding AB (publ) | -50.75 Million SEK | 124.862% |
| SciBase Holding AB (publ) | 16.03 Million SEK | 21.319% |
| ScandiDos AB (publ) | 47.55 Million SEK | 73.467% |
| Sectra AB (publ) | 557.55 Million SEK | 97.737% |
| Sedana Medical AB (publ) | 108.98 Million SEK | 88.422% |
| Senzime AB (publ) | 8.33 Million SEK | -51.313% |
| SpectraCure AB (publ) | -9.22 Million SEK | 236.81% |
| Stille AB | 132.17 Million SEK | 90.453% |
| Vitrolife AB (publ) | 1.97 Billion SEK | 99.362% |
| Xvivo Perfusion AB (publ) | 416.91 Million SEK | 96.973% |